Stock comparison
Haemonetics
InMode
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HAE
Haemonetics
Market cap
$2.98B
Sector
Healthcare
INMD
InMode
Market cap
$870.55M
Sector
Healthcare
Overall winner
Haemonetics HAE
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HAE | INMD | Winner |
|---|---|---|---|
| Warren Buffett | 70B | 56C | HAE |
| Benjamin Graham | 85A | 52C | HAE |
| Philip Fisher | 60C | 46D | HAE |
| Peter Lynch | 54C | 24F | HAE |
| Joel Greenblatt | 31F | 27F | HAE |
| Charlie Munger | 54D | 58C | INMD |
| Terry Smith | 55D | 59C | INMD |
Side-by-side metrics
| Metric | HAE | INMD |
|---|---|---|
| Market cap | $2.98B | $870.55M |
| P/E (TTM) | 24.8x | 10.0x |
| EV/EBIT | 14.1x | 5.6x |
| ROIC (TTM) | 8.37% | 10.11% |
| Gross margin | 55.74% | 77.84% |
| Net margin | 7.29% | 23.27% |
| Revenue CAGR 5y | 7.65% | 0.89% |
| EPS CAGR 5y | 24.62% | -8.07% |
| Debt / Equity | 1.5x | 0.0x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HAE leads on
- EPS CAGR 5y24.62%vs -8.07%+133%
- Revenue CAGR 5y7.65%vs 0.89%+88%
- Market cap$2.98Bvs $870.55M+71%
INMD leads on
- Debt / Equity0.0xvs 1.5x+100%
- Net margin23.27%vs 7.29%+69%
- EV/EBIT5.6xvs 14.1x+60%
- P/E (TTM)10.0xvs 24.8x+60%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.